Could we all have lifelong robust immunity? Dr Carolien van de Sandt, Murdoch Children’s Research Institute, Melbourne Making proteins with AI: Dr Rhys Grinter, Bio21 Institute, The ...
Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0™ principles with sustainable ...
INTENDED FOR MEDIA AND BUSINESS INVESTORS ONLY Summit, New Jersey, USA | 21 October, 2025 – CSL Seqirus, a global leader in seasonal influenza prevention (ASX: CSL), has shared new ...
CSL Seqirus, a business of CSL (ASX:CSL) today announced that it will be presenting 14 abstracts at the European Scientific Working group on ...
Melbourne, Australia – 17 October 2025 – CSL has announced that the Science Based Targets initiative (SBTi) has approved CSL’s near-term science-based emissions reduction targets. These are: CSL ...
OTTAWA, Ontario, Oct. 6, 2025 /PRNewswire/ -- CSL Behring Canada Inc., a business unit of global biopharma leader CSL, today announced that it has signed a Letter of Intent (LOI) with the pan-Canadian ...
Melbourne, Australia – 16 September 2025 CSL today announced it has entered into a strategic collaboration with privately held Dutch biotech company VarmX BV to support the company’s development of ...
This historic approval of the world's first Self-Amplifying messenger RNA (sa-mRNA) COVID-19 Vaccine underscores CSL's promise to develop and deliver innovations when there is a public health need ...
Melbourne, Australia – 16 September 2025 CSL today announced it has entered into a strategic collaboration with privately held Dutch biotech company VarmX BV to support the company’s... CSL Behring ...
ANDEMBRY is the first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks in people with HAE The authorization of ANDEMBRY expands CSL's HAE franchise and underscores ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback